A Novel Nanocatalyst for Combined Chemodynamic and 
Starvation Therapy in Cancer Treatment

Yingying Yang; Jinrong Situ; Hongzhang Yan; Lingle Zhang; Yingsheng Cheng*

doi:10.18686/frim.v2i5.4528

A Novel Nanocatalyst for Combined Chemodynamic and Starvation Therapy in Cancer Treatment

Yingying Yang, Jinrong Situ, Hongzhang Yan, Lingle Zhang, Yingsheng Cheng*

Abstract

Cancer remains a significant challenge due to the limitations and side effects of tra- ditional treatments. Novel minimally invasive
therapies are essential to enhance patient outcomes. This study introduces MIL-101(Fe)@MnO2 @Gox/HA, a nanocatalyst that com- bines
glucose oxidase and manganese dioxide in an iron-based metal-organic framework (MOF) coated with hyaluronic acid. This nanoplatform
demonstrates strong water affin- ity, tumor targeting, and durability. MIL-101(Fe)@MnO2 @Gox/HA presents a promis- ing anti-cancer strategy, warranting further investigation to enhance tumor targeting and treatment efficacy.

Keywords

Nanocatalyst; Chemodynamic Therapy; Starvation Therapy; Cancer Treatment

Full Text:

PDF

Included Database

References

[1] Bhupender S. Chhikara and Keykavous Parang. Global Cancer Statistics 2022: the trends projection analysis. In: Chemical Biology

Letters 10 (2023), pp. 451451.

[2] F. Bray et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. In:

(2018).

[3] Parris Kidd. Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti- aging potential. In: Altern Med Rev 16.4

(2011), pp. 355364.

[4] Shuangjiang Yu et al. Advances in nanomedicine for cancer starvation therapy. In: Ther- anostics 9.26 (2019). Publisher: Ivyspring

International Publisher, p. 8026.

[5] Chunhui Wang et al. Glucose Oxidase-Related Cancer Therapies. en. In: Advanced Ther- apeutics 3.10 (Oct. 2020), p. 2000110. issn:

2366-3987, 2366-3987.

DOI: http://dx.doi.org/10.18686/frim.v2i5.4528

Refbacks

There are currently no refbacks.